Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The drug was administered once every 4 weeks. Other Names: Tocilizumab Injection placebo control”In the company’s words, NCT06726096 on ClinicalTrials.gov
- Tested for
- Anti IL-6R (2 trials), Rheumatoid Arthritis (RA), Castleman's Disease, Multicentric, Idiopathic Multicentric Castleman's Disease
- Main trialPhase 3
- “A multicenter, randomized, double-blind, placebo-controlled, and active drug-controlled Phase III pivotal clinical trial of recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the treatment of moderate-to-severe active rheumatoid arthritis with poor response to methotrexate”In the company’s words, NCT06726096 on ClinicalTrials.gov
Other drugs for Rheumatoid Arthritis (RA)
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up1
- 9 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Enrolling by invitation | 20 Apr 2026 | Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis | |
| Phase 3Recruiting | 9 Jun 2027 | Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease | |
| Phase 2Active, not recruiting | 27 Nov 2022 | A Study of Anti-IL-6R mAb Injection in Patients With iMCD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026